AbbVievsImmunityBio

ABBV and IBRX stock compared: price, dividend, valuation and results, from SEC filings.

IBRX

ImmunityBio, Inc.

$6.02

Value $6.2B

-0.82%
IBRX's page

AbbVie (ABBV) has a market value of $522B and ImmunityBio (IBRX) $6.2B. Over the last year, with dividends, ABBV moved +30.3% and IBRX +192.2%. Dividend yield: ABBV 2.35%, IBRX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$522B

    IBRX$6.2B

    ABBV is 84 times IBRX

  • Revenue, 12 months

    ABBV$66.0B

    IBRX$183M

    ABBV is 362 times IBRX

  • Net income, 12 months

    ABBV$10.3B

    IBRX-$1.1B

  • Operating margin

    ABBV32.2%

    IBRX-150.2%

    182.4 points apart

  • ROIC

    ABBV25.7%

    IBRX–

  • P/E

    ABBV50.7

    IBRX–

  • Dividend yield

    ABBV2.4%

    IBRX0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.5%

    IBRX-22.0%

    223.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.5%

IBRX-22.0%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsIBRXWith dividends
1 year since November 12, 2025+30.3%Price +26.5%+192.2%Price +192.2%
3 years since November 13, 2023+135.3%+33.0% a yearPrice +112.8%+75.0%+20.5% a yearPrice +75.0%
5 years since November 12, 2021+201.5%+24.7% a yearPrice +152.2%-22.0%-4.9% a yearPrice -22.0%
10 years since November 16, 2016+620.7%+21.8% a yearPrice +379.4%-21.7%-2.4% a yearPrice -21.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieIBRXImmunityBio

Valuation

ABBVIBRX
Valuation
Price$295.03$6.02
Market value$522B$6.2B
Enterprise value (EV)$592B–
P/E50.7–
P/E, 5-year median57.0–
P/B––
EV/EBIT27.9–
Free cash flow yield3.6%–

Results and growth

ABBVIBRX
Results and growth
Revenue, 12 months$66.0B$183M
Net income, 12 months$10.3B-$1.1B
Free cash flow, 12 months$18.9B-$297M
Earnings per share, 12 months$5.81-$1.08
Revenue growth, year on year8.6%668.3%
Revenue growth a year, past+5.9%over 5 years+184.8%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVIBRX
Margins and returns on capital
Gross margin73.7%98.8%
Operating margin32.2%-150.2%
Net margin15.7%-607.8%
ROIC25.7%–
ROE––

Balance sheet

ABBVIBRX
Balance sheet
Cash$10.8B$334M
Total debt$80.9B–
Net debt / EBITDA3.2–
Interest cover7.1×-4.5×

Dividends and buybacks

ABBVIBRX
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or IBRX

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or ImmunityBio?

By market value, AbbVie ($522B) is about 84.3 times ImmunityBio ($6.2B), at today's prices.

How did ABBV and IBRX stock do over the last 10 years?

Since November 16, 2016, ABBV's price moved +379.4% and IBRX's -21.7%. With dividends: ABBV +620.7% (+21.8% a year), IBRX -21.7% (-2.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or IBRX?

The dividend yield at today's price is 2.35% for AbbVie and none for ImmunityBio. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or ImmunityBio?

Over the last twelve months, the net margin was 15.7% for AbbVie and -607.8% for ImmunityBio, and the operating margin 32.2% and -150.2%. Revenue was $66.0B and $183M.

Which is the better investment, AbbVie or ImmunityBio?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.